Literature DB >> 29450340

Ocular surface - a complex and vulnerable adoptive environment for topical glaucoma treatment.

Vasile Potop1.   

Abstract

Ocular surface is a complex functional unit in which tissues so different as structure and function harmonize to produce a very short life (15-45 sec) film - tear film essential for the quality of the vision. With age, the ocular surface undergoes a physiological decline, often with a limitation of its functionality. Administration of topical glaucoma treatment itself constitutes a solicitation of the ocular surface and the nature of "accessories" included in this "drop glaucoma treatment", that might be the last straw which breaks the fragile balance or aggravates a previously nonexistent suffering subclinical symptomatology by opening and inducing reactions to treatment. Topical treatment in glaucoma could have the complex aspect of an adoption. Every adoption is a delicate and unpredictable phenomenon. Success does mean harmony and coexistence. For the adoption to succeed, one needs to know well the adoptive environment, the adopted element and the science and art to harmonize them together.

Entities:  

Keywords:  ocular surface; tear film; topical glaucoma treatment

Mesh:

Substances:

Year:  2016        PMID: 29450340      PMCID: PMC5720127     

Source DB:  PubMed          Journal:  Rom J Ophthalmol        ISSN: 2457-4325


  30 in total

Review 1.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

Review 2.  Tear dynamics and dry eye.

Authors:  K Tsubota
Journal:  Prog Retin Eye Res       Date:  1998-10       Impact factor: 21.198

3.  Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.

Authors:  Y Kitazawa; P Smith; N Sasaki; S Kotake; K Bae; Y Iwamoto
Journal:  Eye (Lond)       Date:  2011-06-24       Impact factor: 3.775

Review 4.  Allergic reaction to topical eyedrops.

Authors:  Christophe Baudouin
Journal:  Curr Opin Allergy Clin Immunol       Date:  2005-10

5.  Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

Authors:  Hannu Uusitalo; Enping Chen; Norbert Pfeiffer; Françoise Brignole-Baudouin; Kai Kaarniranta; Markku Leino; Päivi Puska; Elina Palmgren; Thomas Hamacher; Günter Hofmann; Gernot Petzold; Ulrich Richter; Tobias Riedel; Martin Winter; Auli Ropo
Journal:  Acta Ophthalmol       Date:  2010-05       Impact factor: 3.761

6.  Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells.

Authors:  Masahiko Ayaki; Atsuo Iwasawa; Yoichi Inoue
Journal:  Clin Ophthalmol       Date:  2010-10-21

Review 7.  Tear physiology and dry eyes.

Authors:  F J Holly; M A Lemp
Journal:  Surv Ophthalmol       Date:  1977 Sep-Oct       Impact factor: 6.048

8.  Ocular symptoms and signs with preserved and preservative-free glaucoma medications.

Authors:  N Jaenen; C Baudouin; P Pouliquen; G Manni; A Figueiredo; T Zeyen
Journal:  Eur J Ophthalmol       Date:  2007 May-Jun       Impact factor: 2.597

9.  Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy.

Authors:  Kenji Inoue; Kazuko Okugawa; Satoshi Kato; Yuji Inoue; Goji Tomita; Tetsuro Oshika; Shiro Amano
Journal:  J Glaucoma       Date:  2003-12       Impact factor: 2.503

10.  Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects.

Authors:  Naim Terai; Matthias Müller-Holz; Eberhard Spoerl; Lutz E Pillunat
Journal:  Clin Ophthalmol       Date:  2011-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.